MOSCOW, May 9. /TASS/. Russia’s Sputnik V coronavirus vaccine may be supplied to Germany in June, with talks on that matter continuing, the Russian Direct Investment Fund said on Sunday on Sputnik V’s Telegram channel.
"Talks with Germany on purchased of the vaccine continue. The Sputnik V vaccine may be supplied to Germany this June, and not to the prejudice to supplies to other countries," it said.
Germany’s Bild reported earlier on Sunday that talks on Germany’s possible purchase of the Russian vaccine had allegedly come to a dead end. The Russian Direct Investment Fund refuted these reports as untrue.
"Bild’s reports are not true and can be seen as an example of a disinformation campaign geared to bar the Russian and other similar vaccines from entering the European and other markets. In the recent time, the Bild newspaper has published more than 15 such articles attacking the Sputnik V vaccine that contain wrong facts based on information from anonymous sources," it said.
Germany repeatedly expressed its principled readiness to use vaccines developed outside the European Union, in particular Russia’s Sputnik V. Both German Chancellor Angela Merkel and Health Minister Jens Spahn said that a vaccine could be used in Germany only after being certified by the European Medicines Agency (EMA). Spahn said earlier that Germany planned to hold bilateral talks with Russia on possible supplies of Sputnik V in case of its registration in the European Union.
Russia was the world’s first to register an anti-coronavirus vaccine in August 2020. The vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry, was given the name Sputnik V. It is a vector vaccine based on the human adenovirus
The vaccine’s efficacy proved to be 97.6% based on the analysis of the coronavirus incidence data among Russians inoculated with both shots of the vaccine in a period from December 5, 2020 to March 31, 20201.
The vaccine has been registered in around 61 world nations, with an overall population of more than three billion.
The European Medicines Agency said on March 4 it had begun the Sputnik V evaluation procedures to look at its compliance with the EU efficacy, safety and quality standards. The Agency anticipates that the registration of the Russian vaccine could be over by late May.